*Includes access to two (2) webinars + Q&A, exclusive product specials, clinical tools and more!
REGISTER NOW FOR FREE!
LEARN FROM LEADING PROFESSIONALS FROM THE BioGaia SCIENTIFIC TEAM (SWEDEN)
In this 2-part mini-series as they take you through the history and latest evidence for probiotics prescribing.
Join us as they cover the evolution of L. reuteri and discuss evidence-based prescribing protocols for challenging health conditions
Join us as they cover the evolution of L. reuteri and discuss evidence-based prescribing protocols for challenging health conditions
arrow_drop_down_circle
Divider Text
PART 1
The Coevolution of L. reuteri DSM 17938 Alongside Humans
The Coevolution of L. reuteri DSM 17938 Alongside Humans
Tuesday 9th April 2024 at 6:00 pm AEST
Many probiotic formulations include various Limosilactobacillus species, some of which are commonly present in the human intestine. Limosilactobacillus reuteri holds particular significance as a probiotic bacterium due to its coevolution with various animal hosts, including humans, and its secretion of anti-microbial compounds that inhibit other bacteria.
During this webinar, Lotta will take you on a journey through the history of L. reuteri DSM 17938 and discuss:
- The symbiotic relationship between L. reuteri DSM 17938 and humans
- How this relationship may be harnessed to promote health
- How L. reuteri DSM 17938 has diversified over time as a result of host-driven evolution
arrow_drop_down_circle
Divider Text
PART 2
Emerging Research in the field of probiotics
Emerging Research in the field of probiotics
Tuesday 18th June 2024 at 6:00pm AEST
Over the last two decades, there has been a significant transformation in our comprehension of the microbiome's role in human host physiology. Ground-breaking studies have revealed that prokaryotic residents, in comparison to human cells and genes, make an equivalent contribution in terms of cell numbers and a considerably higher contribution in terms of genes to the human "holobiont." This microbial influence extends across various mammalian processes, encompassing digestion, metabolism, immunity, and even brain functions.[i]
This research continues to evolve rapidly, and in this webinar, Sara & Jakob will discuss the exciting results emerging from an ongoing study looking at the impact of L. reuteri probiotic strains on irritable bowel syndrome (IBS). They’ll share:
This research continues to evolve rapidly, and in this webinar, Sara & Jakob will discuss the exciting results emerging from an ongoing study looking at the impact of L. reuteri probiotic strains on irritable bowel syndrome (IBS). They’ll share:
- What pathophysiological mechanisms underlie IBD & IBS
- Which probiotic strains have demonstrated ability to alleviate drivers and symptoms of IBD & IBS
- How to incorporate probiotics in clinical protocols to alleviate common gastrointestinal conditions
[i] Puschhof, J., & Elinav, E. (2023). Human microbiome research: Growing pains and future promises. PLoS biology, 21(3), e3002053.
arrow_drop_down_circle
Divider Text
Lotta Johansson
Lotta Johansson is a microbiologist with a special interest in the human microbiome.
She has 35 years’ experience in the field of probiotics and is currently based in Stockholm, Sweden, where she specialises in research focussed on the Limosilactobacillus reuteri species of probiotic.
Lotta has a particular passion for communicating the science of probiotics, and helping people appreciate, cherish, and nurture their microbiome.
She has 35 years’ experience in the field of probiotics and is currently based in Stockholm, Sweden, where she specialises in research focussed on the Limosilactobacillus reuteri species of probiotic.
Lotta has a particular passion for communicating the science of probiotics, and helping people appreciate, cherish, and nurture their microbiome.
Sara Appelgren
Sara Appelgren, BSc, MNutr
Sara is a biochemist and nutritionist with a background in infant nutrition, and a special interest in probiotics.
She has a Master’s in Nutrition and is based in Stockholm, Sweden, where she works as the Scientific Affairs Manager of leading probiotics manufacturer BioGaia.
In her role at BioGaia, Sara works within scientific communications, being the link between science and communications.
BioGaia is a science driven company, which allows Sara to indulge her passion for research and evidence-based nutritional practice.
Jakob Axelsson
Jakob Axelsson, BSc Chemistry, MSci Biochemistry, DPhil
Jakob Axelsson, based in Sweden, is currently a Research Manager at Biogaia Ab, bringing experience from previous roles at Clinical Laserthermia Systems Ab (Clsb), Axichem, Lund University and University of California, San Diego.
Jakob Axelsson holds a 2004 - 2008 Doctor of Philosophy in Philosophy @ Lund University. With a robust skill set that includes Cell Culture, Immunohistochemistry, Cell Biology, Biochemistry, Protein Chemistry and more, Jakob Axelsson contributes valuable insights to the industry.